17,261 trials
Meningococcal Disease
Primary: Summary of Memory B Cells Per 2 x 105 LOC by Serogroup A, C, W-135 and Y — 2.10; 1.80; 1.72; 2.57 B cells per 2x100000 lymphocytes — p=0.69
Atherosclerosis · Myocardial Ischemia · Myocardial Infarction
Primary: Number of Participants Experiencing Adverse Events (AEs) Who Underwent Percutaneous Coronary Interventions (PCI) — 40; 30; 21 Participants
Social Anxiety Disorder
Primary: Social Cooperation — 4.42; 4.69 Ball tosses
Coronary Artery Disease · Endothelial Dysfunction
Primary: Change During Darusentan Treatment in the Markovian Homogeneity Number, a Value That Quantitates Myocardial Perfusion Heterogeneity — 0.33; 0.39 No units
Onychomycosis
Primary: Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360 — 2; 27 participants
Tetanus · Hepatitis B · Haemophilus Influenzae Type b
Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Above the Cut-off — 204; 188 Participants
Colorectal Cancer
Primary: Percentage of Participants With Pathological Complete Response (pCR) — 10.00 percentage of participants — p=1.00
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Purpura, Thrombocytopenic, Idiopathic
Primary: Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 2 — 8 Participants
Active Ulcerative Colitis
Primary: Percentage of Participants With a Clinical Response — 53; 44 percentage of participants
Asthma
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 - 24h (AUC 0-24) Response. — 0.219; 0.217 Liters
Hypoglycemia
Primary: Percentage of Responders — 83.3; 25; 50; 75 percentage of participants
Acute Coronary Syndrome · Depression
Primary: Depressive Symptom Reduction — -6.6; -10.1 Scores on a scale — p=0.01
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Infection
Primary: Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100 — 37.3 Percentage of patients developing aGVHD
Epilepsy
Primary: The Percentage of Participants With a 50% or Greater Reduction in Seizure Frequency (Further Referred to as "Responders") in a Treatment Period Compared to the Baseline…